- Reaction score
- 338
If you are unfamiliar with PGD2 start here:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3982925/
I'm a somewhat technical person so this will be somewhat technical:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367156/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367156/
Some information that might help with understanding:
The point of this post:
Basically this is evidence for this happening:
Increase in pgd2 -> Increase in L-PGDS expression(This is assuming that macrophages in the scalp behave similiarly) -> increase in PGD2
Assuming this positive feedback loop exists then inhibiting PGD2 results in a decrease of L-PGDS which results in decreased production of PGD2. And by inhibiting PGD2, I mean actually lowering the levels of PGD2 in the scalp not necessarily GPR-44 like seti inhibits. Basically you need to drop the PGD2 levels in the scalp. Either with something that binds to PGD2 or a gene transcription blocker for PTGDS. Legit PTGDS inhibs are too expensive so we need to attack the problem upstream.
But there's more to it you still have production of PGD2 in Mast cells and you also still have the question of H-PGDS as well.
Basically the big open question would be "Is the overexpression of PGD2 in the scalp reversible?"
This also suggest that an alternate way of preventing the transcription of PTGDS using a molecule that binds to Nrf2 would be a therapy approach.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3982925/
I'm a somewhat technical person so this will be somewhat technical:
Nrf2 is a transcription factor that protects against inflammatory diseases, but the underlying mechanism of this effect remains unclear. Here, we report that Nrf2 uses lipocalin–prostaglandin D synthase (L-PGDS) as a mechanism for suppressing inflammation.
Exogenously added prostaglandin D2 (PGD2) induced L-PGDS expression in bone-marrow-derived macrophages (BMDMs), suggesting a positive feedback loop between L-PGDS expression and PGD2. Unlike lipopolysaccharide (LPS)-induced L-PGDS expression, PGD2-mediated expression was independent of MAPK, PU.1, or TLR4. Sequence analysis located a putative Nrf2 binding site in the murine L-PGDS promoter, to which Nrf2 bound when treated with PGD2. Chemical activation, or overexpression, of Nrf2 was sufficient to induce L-PGDS expression in macrophages, BMDMs, or lungs of Nrf2-knockout (KO) mice, but treatment with PGD2 failed to do so, suggesting a pivotal role for Nrf2 in the expression of L-PGDS. Consistent with this, expression of Nrf2 in the lungs of Nrf2-KO mice was sufficient to induce the expression of L-PGDS and to reduce neutrophilic lung inflammation elicited by LPS. Furthermore, expression of L-PGDS in mouse lungs decreased neutrophilic infiltration, ameliorating lung inflammation in mice. Together, our results show that Nrf2, activated by PGD2, induced L-PGDS expression, resulting in decreased inflammation. We suggest that the positive feedback induction of L-PGDS by PGD2 is part of the mechanism by which Nrf2 regulates inflammation.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367156/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367156/
Some information that might help with understanding:
- 1. Basically you have 2 versions of PTGDS(The enzyme that is used to create PGD2 when this gene expression is increased it results in an increase of the enzyme that results in an increase in PGD2 via the Archiadonic Acid chain.)
- 2. Lipocalin-prostaglandin D synthase = L-PGDS = Lipocalin PTGDS
- 3. The is also Hematopoietic PTGDS.
- 4. Lipocalin PTGDS is the type of PTGDS that was observed to have elevated levels in cases of Androgenetic Alopecia back in 2012 by cots.
- 5. PGD2 serves differrent immune regulating functions in the body depending where it is. In the scalp it likely is what induces inflammation via activation of GPR-44.
The point of this post:
Basically this is evidence for this happening:
Increase in pgd2 -> Increase in L-PGDS expression(This is assuming that macrophages in the scalp behave similiarly) -> increase in PGD2
Assuming this positive feedback loop exists then inhibiting PGD2 results in a decrease of L-PGDS which results in decreased production of PGD2. And by inhibiting PGD2, I mean actually lowering the levels of PGD2 in the scalp not necessarily GPR-44 like seti inhibits. Basically you need to drop the PGD2 levels in the scalp. Either with something that binds to PGD2 or a gene transcription blocker for PTGDS. Legit PTGDS inhibs are too expensive so we need to attack the problem upstream.
But there's more to it you still have production of PGD2 in Mast cells and you also still have the question of H-PGDS as well.
Basically the big open question would be "Is the overexpression of PGD2 in the scalp reversible?"
This also suggest that an alternate way of preventing the transcription of PTGDS using a molecule that binds to Nrf2 would be a therapy approach.
Last edited: